Praziquantel slow-released Implants for animals and preparation method thereof

Abstract

The invention relates to a veterinary praziquantel slow-release implant in the field of veterinary drug and a method for preparing the same. The slow-release implant comprises the following compositions in percentage by weight: 10 to 70 percent of praziquantel, 30 to 90 percent of a biocompatible material and 0 to 60 percent of a hydrophilic release regulator; the method for preparing the slow-release implant comprises the following steps: the praziquantel, the biocompatible material and the hydrophilic release regulator are weighed according to weight mixture ratio, thrown into an extruder, stirred and extruded out by a neck ring mold; a mixture of the extruded drug and material is cooled and solidified; and the fully cooled and solidified mixture of the drug and material is cut into drug bars so as to obtain the praziquantel slow-release implant. The method avoids the use of an organic solvent in the process of the preparation production and ensures the precision of the content of the preparation drug and the repeatability of preparation production.

Description

technical field [0001] The invention relates to a sustained-release implant in the field of pharmaceutical technology and a preparation method thereof, in particular to a sustained-release praziquantel implant for animals and a preparation method thereof. Background technique [0002] Schistosomiasis and tapeworm are zoonotic parasitic diseases. In particular, schistosomiasis has been on the rise in recent years, which has attracted great attention from the country. When livestock are seriously infected, it often leads to emaciation of the affected animal. If the prevention and control is not timely, it is easy to cause the death of the affected animal and seriously affect the healthy development of animal husbandry. In order to control the above-mentioned parasitic diseases, at present, ordinary praziquantel tablets are mainly administered orally to achieve deworming. However, this treatment has only a temporary curative effect and no long-term preventive effect. In addi...

AI Technical Summary

Problems solved by technology

The inclusion of biocompatible materials not only effectively increases the drug loading capacity, but also significantly improves the utilization rate and action time of the drug through subcutaneous implantation or intramuscular injection. However, the preparation of the above-mentioned inclusion preparations is still There are at least two deficiencies: ① a large amount of organic solvents are used in the inclusion process, and the residue of organic solvents will affect the stability of the pharmaceutical preparation; ② it is difficult to ensure that the drug is completely wrapped by the material during the inclusion process. The drug loading is uncertain, and the preparation process is not reproducible

Although this method avoids the use of toxic organic solvents and the preparation method is relatively simple, there are still at least three shortcomings in the above-mentioned sustained-release injections: ①The temperature-raising and cooling operations involved in the preparation process of the sustained-release injections are time-consuming; ②Drug granules It is also difficult to ensure uniform dispersion in aluminum monostearate castor oil gel, thus, the drug loading of the unit preparation after packaging is uncertain; ③ This production method is not conducive to scale-up production